Philip Morris International updated its fair value estimate to US$203.80, reflecting a constructive outlook on its smoke-free products.
Philip Morris International has updated its fair value estimate from US$193.14 to US$203.80, signaling a higher implied price target range. This adjustment reflects a constructive stance from several firms, including Barclays, Morgan Stanley, Stifel, and BTIG, which have lifted their price targets. Analysts highlight the growth potential of smoke-free products like IQOS and ZYN, balanced by a resilient combustible franchise. While Morgan Stanley trimmed its FY26 EPS view slightly due to currency pressures, firms like Barclays and BTIG emphasize that the growth drivers in pouch and heated tobacco are supportive for the medium-term earnings profile. The update accounts for a shift in revenue growth assumptions and a net profit margin adjustment. Investors are encouraged to the follow the narrative of how smoke-free products affect long-term earnings mix and the role of emerging markets in supporting revenue. The analysis is based on fundamental data and is not intended as financial advice.
Sources
-
Philip Morris gets FDA nod for 11 new nicotine pouches
Reuters
-
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review
Business Wire
-
Zyn Pouches With Higher Nicotine Content Get FDA Authorization
Bloomberg.com
-
Philip Morris International (PM) Stock Fair Value Edges Higher On IQOS And ZYN Optimism
Yahoo Finance
-
FDA Authorizes 11 Flavored Nicotine Pouches
respiratory-therapy.com